![Leah Monteiro](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Leah Monteiro worked as Senior Director-Communications & IR at KalVista Pharmaceuticals, Inc. from 2016 to 2021.
The career history includes roles as Vice President-Investor Relations at DURECT Corp., Senior Manager-Investor Relations at Genzyme Corp., Manager-Corporate Communications at Sesen Bio, Inc., and Vice President-Investor Relations & Communications at Solid Biosciences, Inc. from 2023 to 2024.
Former jobs include positions at KalVista Pharmaceuticals, Inc., DURECT Corp., Genzyme Corp., Sesen Bio, Inc., and Solid Biosciences, Inc.
Eerdere bekende functies van Leah Monteiro
| Bedrijven | Functie | Einde |
|---|---|---|
| SOLID BIOSCIENCES INC. | Investor Relations Contact | 30-04-2024 |
| KALVISTA PHARMA | Investor Relations Contact | 01-12-2021 |
| CARISMA THERAPEUTICS, INC. | Investor Relations Contact | 01-07-2016 |
| DURECT | Investor Relations Contact | - |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Investor Relations Contact | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
16
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
DURECT Corp.
 DURECT Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for pain and chronic diseases | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
Solid Biosciences, Inc.
 Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
KalVista Pharmaceuticals, Inc.
 KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
